Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).

ÖZGÜROĞLU M., Levy B. P., Horinouchi H., Yu J., Grainger E., Phuong P. H., ...More

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023 identifier

  • Publication Type: Conference Paper / Summary Text
  • City: Illinois
  • Country: United States Of America
  • Istanbul University Affiliated: No